Terms: = Lung cancer AND Neurokinin AND Treatment
23 results:
1. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel.
Chiu JWY; Lee SC; Ho JC; Park YH; Chao TC; Kim SB; Lim E; Lin CH; Loi S; Low SY; Teo LLS; Yeo W; Dent R
Drug Saf; 2023 Oct; 46(10):927-949. PubMed ID: 37552439
[TBL] [Abstract] [Full Text] [Related]
2. Impact of the Oncology Care Model on Use of Supportive Care Medications During cancer treatment.
Brooks GA; Landrum MB; Kapadia NS; Liu PH; Wolf R; Riedel LE; Hsu VD; Jhatakia Parekh S; Simon C; Hassol A; Keating NL
J Clin Oncol; 2022 Jun; 40(16):1763-1771. PubMed ID: 35213212
[TBL] [Abstract] [Full Text] [Related]
3. neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR.
Zhang XW; Li L; Hu WQ; Hu MN; Tao Y; Hu H; Miao XK; Yang WL; Zhu Q; Mou LY
Cell Death Dis; 2022 Jan; 13(1):41. PubMed ID: 35013118
[TBL] [Abstract] [Full Text] [Related]
4. A prospective audit on the use of prophylactic antiemetics and rates of CINV in patients receiving carboplatin AUC≥4 or combination anthracycline-cyclophosphamide.
Lo E; Anderson M; Carroll R; Forgeson G; Isaacs R; Jordan J; Satterthwaite L; Wewala N; Fernando J
N Z Med J; 2021 Apr; 134(1533):33-45. PubMed ID: 33927422
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy of active compounds of Chanqin granules on airway neurogenic inflammation induced by PM2.5 in vivo.
Ju Y; Shen R; Yu X
J Tradit Chin Med; 2020 Oct; 40(5):792-802. PubMed ID: 33000580
[TBL] [Abstract] [Full Text] [Related]
6. Aprepitant for Cough in lung cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights.
Smith JA; Harle A; Dockry R; Holt K; Russell P; Molassiotis A; Yorke J; Robinson R; Birrell MA; Belvisi MG; Blackhall F
Am J Respir Crit Care Med; 2021 Mar; 203(6):737-745. PubMed ID: 32966755
[No Abstract] [Full Text] [Related]
7. Aprepitant for Cough Suppression in Advanced lung cancer: A Randomized Trial.
Noronha V; Bhattacharjee A; Patil VM; Joshi A; Menon N; Shah S; Kannan S; Mukadam SA; Maske K; Ishi S; Prabhash K
Chest; 2020 Jun; 157(6):1647-1655. PubMed ID: 31958446
[TBL] [Abstract] [Full Text] [Related]
8. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Navari RM
Expert Opin Drug Saf; 2020 Feb; 19(2):205-210. PubMed ID: 31709853
[No Abstract] [Full Text] [Related]
9. Safety Profile of HTX-019 Administered as an Intravenous Push in cancer Patients: A Retrospective Review.
Walton GD
Adv Ther; 2019 Mar; 36(3):662-669. PubMed ID: 30706408
[TBL] [Abstract] [Full Text] [Related]
10. Aprepitant for refractory nivolumab-induced pruritus.
Ito J; Fujimoto D; Nakamura A; Nagano T; Uehara K; Imai Y; Tomii K
Lung Cancer; 2017 Jul; 109():58-61. PubMed ID: 28577951
[TBL] [Abstract] [Full Text] [Related]
11. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
Okuyama A; Nakamura F; Higashi T
JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
[TBL] [Abstract] [Full Text] [Related]
12. Involvement of substance P and the NK-1 receptor in human pathology.
Muñoz M; Coveñas R
Amino Acids; 2014 Jul; 46(7):1727-50. PubMed ID: 24705689
[TBL] [Abstract] [Full Text] [Related]
13. Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors.
Di Maio M; Bria E; Banna GL; Puglisi F; Garassino MC; Lorusso D; Perrone F
Anticancer Drugs; 2013 Feb; 24(2):99-111. PubMed ID: 23165435
[TBL] [Abstract] [Full Text] [Related]
14. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
[TBL] [Abstract] [Full Text] [Related]
15. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract] [Full Text] [Related]
16. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
[TBL] [Abstract] [Full Text] [Related]
17. [Experience with aprepitant in the prevention of nausea and vomiting caused by highly emetic chemotherapy of lung cancer].
Tamási L; Müller V; Magyar P
Magy Onkol; 2008 Jun; 52(2):179-83. PubMed ID: 18640894
[TBL] [Abstract] [Full Text] [Related]
18. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials.
Gralla RJ; de Wit R; Herrstedt J; Carides AD; Ianus J; Guoguang-Ma J; Evans JK; Horgan KJ
Cancer; 2005 Aug; 104(4):864-8. PubMed ID: 15973669
[TBL] [Abstract] [Full Text] [Related]
19. Drugs to suppress cough.
Chung KF
Expert Opin Investig Drugs; 2005 Jan; 14(1):19-27. PubMed ID: 15709918
[TBL] [Abstract] [Full Text] [Related]
20. Same old story? Do we need to modify our supportive care treatment of elderly cancer patients? Focus on antiemetics.
Gridelli C
Drugs Aging; 2004; 21(13):825-32. PubMed ID: 15493948
[TBL] [Abstract] [Full Text] [Related]
[Next]
